Article Details
Retrieved on: 2025-04-01 12:44:05
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details the development of VX-01, a humanized monoclonal antibody targeting mucormycosis, aligning with biotechnology advancements in immunology. VX-01 enhances immune response and exemplifies biopharmaceutical innovation addressing immune challenges tagged under immunogenicity and antibodies.
Article found on: www.contagionlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here